Articles By Rob Wright, Chief Editor 2011-2021

big pharma in biotechnology
Can Big Pharma Survive In A Big Biotech World?
If you looked up the definition for Big Pharma, you would be surprised if the explanation was not accompanied by a Pfizer logo. The company’s rise to becoming synonymous with Big Pharma began when Pfizer recognized the pharmaceutical success paradox of the 1990s — in order to turn small molecule drugs into commercial blockbuster successes, it was better to be BIG (i.e., BIG budgets, BIG mergers, and BIG sales forces).   Continue Reading..
  • The U.S. Pharmaceutical Industry — Between A Hard Rock Of Hope And A Heartbreak
    4/29/2014

    At the 2014 PhRMA annual meeting he author of the Emmy Award-winning New York Times Series, Life Interrupted, delighted the audience with her response involving a bone marrow transplant with her brother as the donor. This was but one of the powerful experiences gained from attending this year’s PhRMA meeting, appropriately themed — from hope to cures.

  • Astrazeneca’s Biologics Veteran: Applying A Risk-Based Approach To Plan For Capacity
    4/29/2014

    Imagine you are seated at a table preparing to discuss the manufacturing of biologics. The person across from you possesses nearly 40 years’ worth of wisdom on the topic. You, on the other hand, have zero experience in this field. Kind of like a rookie stepping into the batter’s box against Nolan Ryan and understanding that if a 95 mph baseball is coming at his head he has less than .4 seconds to get out of the way.

  • It’s Not The Tool, It’s The Technique
    4/29/2014

    My son plays on his college’s golf team. In the fall he was struggling with his putting. What is the obvious solution needed to fix the problem? Why, to buy a new putter of course. It could not possibly be anything to do with the technique. It must be the tool.

  • Why Death With Dignity In The U.S. Remains The Holy Grail
    4/9/2014

    After making the painful decision to "put down" our family dog, it made me wonder about the end-of-life decision making process for humans? What are the costs? What's considered humane? Is America ready for physician-assisted suicide?

  • Merck Serono’s CEO Belén Garijo – Enabling Risk And Refusing To Play It Safe
    4/1/2014

    Sitting on the secondlevel balcony of the grand ballroom in the historic New York Waldorf-Astoria, my vantage point provides a bird’s-eye view of the floor below. Today, the room serves as a central meeting place for attendees of the sixteenth BIO CEO and Investor Conference. I wonder aloud to my table guest, Belén Garijo, M.D., as to the uniqueness of being interviewed in this venue.

  • Are You Embracing The Life Sciences New Innovation Ecosystem?
    4/1/2014

    At this year’s BIO CEO and Investor Conference in New York, I had the opportunity to meet Annalisa Jenkins, EVP and head of global R&D, Merck Serono. Jenkins has been busy working on a game-changing, singlesource CRO collaboration model with Quintiles. Understanding how and why she did it first requires insight into the leadership approach of her risk-enabling CEO, Belén Garijo (see page 24), followed by Jenkins’ detailed explanation of creating the model, along with some pretty good advice on building game-changing collaborations (see page 30). Finalizing this collaboration model won’t make her schedule any less busy; in fact, it just got busier.

  • The CMO Leadership Awards – A Celebration Of Continuous Improvement
    3/28/2014

    When we were planning this year’s CMO Leadership Awards reception and ceremony, we could have simply implemented the previous year’s format and been done with it. After all, that year’s ceremony — our first ever — was a success, with 190 attendees and lots of winners.

  • The Future Of Clinical Trials In An Outsourced Model
    3/5/2014

    Throughout human history people have held a fascination with trying to predict the future, employing a variety of tools — crystal balls, palm readings, tarot cards, or my personal favorite, the Magic 8 Ball. Scientists typically use data when forecasting the future.

  • How To Improve Clinical Trials – Some Good Old-Fashioned Wisdom
    3/5/2014

    Intel cofounder Gordon Moore predicted in 1965 that the number of transistors on an integrated circuit would double approximately every two years. What came to be known as Moore’s Law has basically held true ever since.

Rob Wright author page

Rob Wright

Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL